Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy

Heethuis, S.E.; Rossum, Peter S.N. van; Lips, Irene M.; Goense, Lucas; Voncken, Francine E.M.; Reerink, O.; Hillegersberg, Richard van; Ruurda, Jelle P.; Philippens, M.E.P.; Vulpen, Marco van; Meijer, G.J.; Lagendijk, J J W; Lier, Astrid L.H.M.W. van

doi:10.1016/j.radonc.2016.05.009

Cited by 56 publications

(59 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For optimal diagnosis of breast lesions assessment of both tumor morphology and enhancement kinetics is necessary. To understand the pharmacokinetics and in assessing the treatment response of tumors to anti‐cancer treatments, the tumor vascular permeability and perfusion characteristics are used as biomarkers …”

Section: Mri‐related Methods In the Study Of Breast Cancer Metabolismmentioning

confidence: 99%

Application of in vivo MR methods in the study of breast cancer metabolism

Jagannathan

2018

NMR in Biomedicine

View full text Add to dashboard Cite

In the last two decades, various in vivo MR methodologies have been evaluated for their potential in the study of cancer metabolism. During malignant transformation, metabolic alterations occur, leading to morphological and functional changes. Among various MR methods, in vivo MRS has been extensively used in breast cancer to study the metabolism of cells, tissues or whole organs. It provides biochemical information at the metabolite level. Altered choline, phospholipid and energy metabolism has been documented using proton ( 1 H), phosphorus ( 31 P) and carbon ( 13 C) isotopes. Increased levels of choline-containing compounds, phosphomonoesters and phosphodiesters in breast cancer, which are indicative of altered choline and phospholipid metabolism, have been reported using in vivo, in vitro and ex vivo NMR studies. These changes are reversed on successful therapy, which depends on the treatment regimen given.Monitoring the various tumor intermediary metabolic pathways using nuclear spin hyperpolarization of 13 C-labeled substrates by dynamic nuclear polarization has also been recently reported. Furthermore, the utility of various methods such as diffusion, dynamic contrast and perfusion MRI have also been evaluated to study breast tumor metabolism. Parameters such as tumor volume, apparent diffusion coefficient, volume transfer coefficient and extracellular volume ratio are estimated. These parameters provide information on the changes in tumor microstructure, microenvironment, abnormal vasculature, permeability and grade of the tumor. Such changes seen during cancer progression are due to alterations in the tumor metabolism, leading to changes in cell architecture. Due to architectural changes, the tissue mechanical properties are altered; this can be studied using magnetic resonance elastography, which measures the elastic properties of tissues. Moreover, these structural MRI methods can be used to investigate the effect of therapy-induced changes in tumor characteristics. This review discusses the potential of various in vivo MR methodologies in the study of breast cancer metabolism.

show abstract

Section: Mri‐related Methods In the Study Of Breast Cancer Metabolismmentioning

confidence: 99%

Application of in vivo MR methods in the study of breast cancer metabolism

Jagannathan

2018

NMR in Biomedicine

View full text Add to dashboard Cite

show abstract

“…[121] Ar ecent screen of 200 foodstuffs identified roasted barley as ap romisingp hotoacousticc ontrasta gent in mice and humans. [122] Another imaging example is 19 Fm agnetic resonance imaging, and highly selectiveimages of the GI tract can be generated by using perfluorononane on am ouse model. In the study,e ach mouse was orallyg avaged 0.3 mL of perfluorononanea fter fasting for 1h.S ubsequently,a 19 Fr esonator was used for MRI with prone position.…”

Section: Othersmentioning

confidence: 99%

“…[122] Another imaging example is 19 Fm agnetic resonance imaging, and highly selectiveimages of the GI tract can be generated by using perfluorononane on am ouse model. In the study,e ach mouse was orallyg avaged 0.3 mL of perfluorononanea fter fasting for 1h.S ubsequently,a 19 Fr esonator was used for MRI with prone position. Perfluorononane has been approved as an ideal contrast agent with excellent properties,such as biochemical inertness, immiscible characteristics with water,h igh contento ff luorine, low viscosity,a nd good surface tension.…”

Section: Othersmentioning

confidence: 99%

See 1 more Smart Citation

Ingestible Contrast Agents for Gastrointestinal Imaging

2019

View full text Add to dashboard Cite

Gastrointestinal (GI) ailments cover a wide variety of diseases involving the esophagus, stomach, small intestine, large intestine, and rectum. They bring about many inconveniences in daily life in chronic diseases and can even be life threatening in acute cases. Rapid and safe detection approaches are essential for early diagnosis and timely management. Contrast agents for GI imaging can enhance contrast to distinguish abnormal lesions from normal structures. Computed tomography and magnetic resonance imaging are two important diagnostic tools for the evaluation of GI conditions. This review mainly involves several common GI diseases, including inflammatory diseases, intestinal tumors, diarrhea, constipation, and gastroesophageal reflux diseases. Selected contrast agents, such as barium sulfate, iodine‐based agents, gadolinium‐based agents, and others, are summarized. Going forward, continued endeavors are being made to develop more emerging contrast agents for other imaging modalities.

show abstract

“…Several studies have been initiated to preoperatively identify these patients for an organ‐preserving approach, avoiding unnecessary surgery‐related morbidity, followed by active surveillance. In this light, various diagnostic strategies, such as endoscopic biopsies and/or EUS, 18F‐FDG PET(‐CT), diffusion‐weighted, and dynamic contrast–enhanced magnetic resonance imaging (MRI), are being researched to predict response and ultimately avoid surgery in selected patients. The MUNICON‐1 and MUNICON‐2 trials have shown that PET‐based therapy individualization could be a feasible approach for GEJ adenocarcinomas .…”

Section: Complete Responders To Neoadjuvant Therapymentioning

confidence: 99%

Surgical treatment of esophageal cancer in the era of multimodality management

Borggreve

Kingma

Домрачев

et al. 2018

Annals of the New York Academy of Sciences

Self Cite

102

View full text Add to dashboard Cite

Over the last decades, the treatment of resectable esophageal cancer has evolved into a multidisciplinary process in which all players are essential for treatment to be successful. Medical oncologists and radiation oncologists have been increasingly involved since the implementation of neoadjuvant therapy, which has been shown to improve survival. Although esophagectomy is still considered the cornerstone of curative treatment for locally advanced esophageal cancer, it remains associated with considerable postoperative morbidity, despite promising results of minimally invasive techniques. In this light, both physical status and response to neoadjuvant therapy may be important factors for selecting patients who will benefit from surgery. Furthermore, it is important to optimize the entire perioperative trajectory: from the initial outpatient clinic visit to postoperative discharge. Enhanced recovery after surgery is increasingly recognized for esophagectomy and emphasizes perioperative aspects, such as nutrition, physiotherapy, and pain management. To date, several facets of esophageal cancer treatment remain topics of debate, such as the preferred neoadjuvant treatment, anastomotic technique, extent of lymphadenectomy, organization of postoperative care, and the role of surgery beyond locally advanced disease. Here, we describe the current and future perspectives in the surgical treatment of patients with esophageal cancer in the context of the available literature.

show abstract

Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy

Cited by 56 publications

References 40 publications

Application of in vivo MR methods in the study of breast cancer metabolism

Application of in vivo MR methods in the study of breast cancer metabolism

Ingestible Contrast Agents for Gastrointestinal Imaging

Surgical treatment of esophageal cancer in the era of multimodality management

Contact Info

Product

Resources

About